Spots Global Cancer Trial Database for fibrolamellar carcinoma
Every month we try and update this database with for fibrolamellar carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | NCT04134559 | Hepatocellular ... Fibrolamellar C... Liver Cancer Liver Cancer, P... | Pembrolizumab | 0 Years - 30 Years | Dana-Farber Cancer Institute | |
| Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | NCT03533582 | Childhood Hepat... Childhood Malig... Fibrolamellar C... Hepatoblastoma Hepatocellular ... | Carboplatin Cisplatin Doxorubicin Etoposide Fluorouracil Gemcitabine Irinotecan Laboratory Biom... Oxaliplatin Patient Observa... Resection Sorafenib Vincristine Sul... | - 30 Years | Children's Oncology Group | |
| Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02159989 | Advanced Malign... Fibrolamellar C... Metastatic Mali... Ovarian Carcino... Pancreatic Neur... Recurrent Malig... Refractory Mali... Unresectable So... | Sapanisertib Ziv-Aflibercept | 18 Years - | National Cancer Institute (NCI) | |
| KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | NCT05603572 | Hepatocellular ... Fibrolamellar C... | KAT-101 KAT-201 | 18 Years - | Primocure Pharma | |
| KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | NCT05603572 | Hepatocellular ... Fibrolamellar C... | KAT-101 KAT-201 | 18 Years - | Primocure Pharma | |
| Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) | NCT01642186 | Fibrolamellar C... Fibrolamellar L... | everolimus letrozole plus ... combination of ... | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) | NCT01642186 | Fibrolamellar C... Fibrolamellar L... | everolimus letrozole plus ... combination of ... | 12 Years - | Memorial Sloan Kettering Cancer Center | |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | NCT03860272 | Advanced Cancer Angiosarcoma Colorectal Canc... Endometrial Can... Fibrolamellar C... Non-small-cell ... Ovarian Cancer Prostate Cancer | Botensilimab Balstilimab | 18 Years - | Agenus Inc. | |
| Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | NCT05468359 | Refractory Soli... Hepatocellular ... Malignant Solid... Pediatric Cance... Pediatric Solid... Fibrolamellar C... | Atezolizumab Sorafenib Bevacizumab Cyclophosphamid... | - 30 Years | St. Jude Children's Research Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
